October 30th 2024
Providers advised to halt use, monitor patients, and report any complications with BioZorb devices to the FDA.
October 30th 2024
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
MBCC Offers Review of Burgeoning Advancements in Breast Cancer Management
January 24th 2021The virtual 38th Annual Miami Breast Cancer Conference®, hosted by Physicians’ Education Resource®, LLC will feature presentations from industry thought leaders on innovations in the arena of breast cancer treatment, including topics about systemic therapy and beyond.
Read More
Emerging ESR1-Targeted Therapy Added to Abemaciclib to Treat Metastatic ER+/HER2– Breast Cancer
January 22nd 2021In an interview with Targeted Oncology, Senthil Damodaran, MD, PhD, discussed the need for an ESR1-targeted agent for the postmenopausal women with ESR1-positive, locally advanced or metastatic ER-positive/HER2-negative breast cancer.
Read More
Chemotherapy Improves PFS Over Targeted Therapy Combination in HR+, HER- Breast Cancer Subset
January 18th 2021Patients with hormone receptor-positive and HER2-negative, aromatase inhibitor resistant metastatic breast cancer experienced improvement in progression-free survival on treatment with chemotherapy over palbociclib in combination with and endocrine therapy.
Read More
Exploring the Rationale for OP-1250 in Advanced HR-Positive HER2-Negative Breast Cancer
January 12th 2021Erika P. Hamilton, MD, discusses the rationale for exploring OP-1250 monotherapy in an open-label first-in-human multi center phase 1/2 study in adult patients with advanced and/or metastatic hormone receptor-positive, HER2-negative breast cancer.
Read More
Pembrolizumab and Chemotherapy Combo Emerges for Patients With TNBC
December 31st 2020Earlier in the year, Javier Cortes, MD, PhD, presented progression-free survival results from the phase 3 KEYNOTE-355 clinical trial, which showed the importance of the addition of taxanes to a platinum-based regimen in the triple-negative breast cancer space.
Read More
Novel CDK4/6 Inhibitor Combos Shape Future for HR+/HER2– Breast Cancer
December 30th 2020Despite the success of CDK4/6 inhibitors in patients with advanced hormone receptor–positive, HER2-negative breast cancer, acquired resistance develops in many. For these patients, research indicates that treatment sequencing may soon include agents that act on implicated pathways of resistance.
Read More
2020 SABCS Recap: Subgroup Research Enhances Breast Cancer Treatment Paradigm
December 18th 2020Following the 2020 San Antonio Breast Cancer Symposium, Erika P. Hamilton, MD, and William J. Gradishar, MD, shared their key takeaways and insights from the most impactful data presented during this year’s meeting.
Read More
Tesetaxel Plus Capecitabine Combo Improves PFS in HR+ Metastatic Breast Cancer
December 15th 2020Treatment with tesetaxel plus a reduced dose of capecitabine improved progression-free survival in patients with HER2–, HR+ metastatic breast cancer compared with the FDA-approved dose of capecitabine alone.
Read More
iDFS Not Improved 1-Year of Added Palbociclib to Endocrine Therapy in HR+/HER2- Breast Cancer
December 12th 2020In the phase 3 PENELOPE-B clinical trial, adding 1 year of palbociclib to endocrine therapy did not demonstrate improvement in invasive disease-free survival in patients with hormone receptor–positive, HER2-negative breast cancer who are at high risk of relapse following neoadjuvant chemotherapy, according to results presented at the 2020 San Antonio Breast Cancer Symposium.
Read More
For patients with node-negative early breast cancer, RSClin, an intergration of the 21-gene expression assay and clinical pathologic features, provided more prognostic information compared with the 21-gene recurrence score or clinical pathologic features alone, as well as a more precise prediction of absolute chemotherapy benefit.
Read More
Antiematics and Loperamide Resolve GI AEs Related to Oral Paclitaxel Plus Encequidar in mBC
December 12th 2020Using 5- HT3 inhibitors and early intervention with loperamide was shown to manage gastrointestinal adverse events oral paclitaxel and encequidar in patients with metastatic breast cancer, according to a study presented during the San Antonio Breast Cancer Symposium.
Read More
Sacituzumab Govitecan Shows PFS Benefit for Patients With mTNBC and Brain Metastases
December 11th 2020Sacituzumab govitecan led to improvements in response rates and progression-free survival (PFS) compared with chemotherapy for patients with metastatic triple-negative breast cancer who had stable brain metastases in a subgroup analysis from the phase 3 ASCENT trial.
Read More
In the phase 3 PROTECTIVE-2 trial, patient with breast cancer who received plinabulin and pegfilgrastim experienced a reduction in the incidence of profound neutropenia that was 53% more effective than that of chemotherapy, according to findings presented during the 2020 San Antonio Breast Cancer Symposium.
Read More
GP2/GM-CSF Combination Induces 100% Disease-Free Survival Rate at 5 years in HER2 3+ Breast Cancer
December 11th 2020The GP2 immunotherapy in combination with granulocyte-macrophage colony-stimulating factor induced a 100% disease-free survival with potent responses as treatment of patients with HER2/neu 3–positive disease who received adjuvant trastuzumab .
Read More
Adding Atezolizumab to Chemotherapy Improves Patient Outcomes in Early TNBC
December 11th 2020Pathologic complete responses were improved when neoadjuvant atezolizumab was added to nab-paclitaxel followed by doxorubicin plus cyclophosphamide compared with placebo in combination with chemotherapy as treatment of patients with early triple-negative breast cancer without adding additional treatment burden to patients.
Read More
Ipatasertib Plus Paclitaxel Combo Fails to Improve PFS in PIK3CA/AKT1/PTEN-Altered TNBC
December 11th 2020Ipatasertib in combination with paclitaxel failed to demonstrate a significant improvement in progression-free survival compared with placebo plus paclitaxel as treatment of patients with PIK3CA/AKT1/PTEN-altered locally advanced, unresectable or metastatic triple-negative breast cancer.
Read More
Sacituzumab govitecan demonstrated clinical benefit compared with physician’s choice of therapy as treatment of patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression, but greater efficacy was seen in patients with a medium or high Trop-2 score.
Read More